Completed
OBSERVATIONAL
NCT06507475
Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study aims to describe the effectiveness of oral semaglutide on glycemic control and body weight control and describe characteristics of type 2 diabetes (T2D) adult patients who are being treated with oral semaglutide in Thailand. Data of eligible patients with T2D will be collected via electronic medical record or paper-format chart review to assess the effectiveness of oral semaglutide. Total study duration for the individual patient will be six months from baseline. The study duration expands within the window period will be 12 months from baseline which will be the optional visit.
Interventions
Name:
Semaglutide
Type:
DRUG
Description:
Participants treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
Primary Outcomes
Measure:
Change in Glycated Haemoglobin (HbA1c)
TimeFrame:
Baseline (week 0), end of study (week 26)
Description:
Measured in percentage-point of HbA1c.
Trial Information
NCT ID
NCT06507475
Status
Completed
Study Type
OBSERVATIONAL
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025